Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.60 |
| ▸ | MTNR1B | P49286 | 5/20 | 0.50 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | HCRTR1 | O43613 | 6/20 | 0.46 |
| ▸ | HCRTR2 | O43614 | 5/20 | 0.46 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4340905 | 0.89 | CYP3A4 (0.58) | CYP3A4CYP2D6CYP2C19MTNR1BMTNR1A | |
| SCHEMBL3541010 | 0.86 | CYP3A4 (0.64) | CYP3A4CYP2D6CYP2C19MTNR1BMTNR1A | |
| SCHEMBL5090978 | 0.86 | CYP3A4 (0.64) | CYP3A4CYP2D6CYP2C19MTNR1BMTNR1A | |
| SCHEMBL4348524 | 0.83 | CYP3A4 (0.56) | CYP3A4CYP2D6CYP2C19MTNR1BMTNR1A | |
| SCHEMBL5094541 | 0.82 | CYP3A4 (0.59) | CYP3A4CYP2D6CYP2C19MTNR1BMTNR1A | |
| SCHEMBL4349292 | 0.82 | CYP3A4 (0.55) | CYP3A4CYP2D6CYP2C19MTNR1BMTNR1A | |
| SCHEMBL4344459 | 0.82 | CYP2D6 (0.58) | CYP3A4CYP2D6CYP2C19MTNR1BMTNR1A | |
| SCHEMBL25142601 | 0.81 | CYP2D6 (0.67) | CYP3A4CYP2D6CYP2C19MTNR1BMTNR1A | |
| SCHEMBL4489157 | 0.81 | CYP2D6 (0.62) | CYP3A4CYP2D6CYP2C19MTNR1BMTNR1A | |
| SCHEMBL4345347 | 0.81 | CYP2D6 (0.58) | CYP3A4CYP2D6CYP2C19MTNR1BMTNR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8507523-B2 | anticarcinogenic agents such as 6,7-dimethoxy-1-(4-pyridin-4-ylbenzyl)-1,2,3,4-tetrahydroisoquinoline hydrochloride salt, used for treating gliomas or retinoblastomas; side effect reduction | THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2013-08-13 | — | — | US | disclosed |
| US-8507523-B2 | anticarcinogenic agents such as 6,7-dimethoxy-1-(4-pyridin-4-ylbenzyl)-1,2,3,4-tetrahydroisoquinoline hydrochloride salt, used for treating gliomas or retinoblastomas; side effect reduction | THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2013-08-13 | — | — | US | disclosed |
| US-8507523-B2 | anticarcinogenic agents such as 6,7-dimethoxy-1-(4-pyridin-4-ylbenzyl)-1,2,3,4-tetrahydroisoquinoline hydrochloride salt, used for treating gliomas or retinoblastomas; side effect reduction | THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2013-08-13 | — | — | US | disclosed |
| EP-2099303-A1 | THERAPEUTIC TETRAHYDROISOQUINOLINE-BASED COMPOSITIONS FOR CANCER THERAPY | The University of Tennessee Research Foundation (US) | 2009-09-16 | — | — | EP | disclosed |
| US-20080146597-A1 | Therapeutic Tetrahydroisoquinoline-Based Compositions for Cancer Therapy | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2008-06-19 | — | — | US | disclosed |
| US-20080146597-A1 | Therapeutic Tetrahydroisoquinoline-Based Compositions for Cancer Therapy | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2008-06-19 | — | — | US | disclosed |
| WO-2008064329-A1 | THERAPEUTIC TETRAHYDROISOQUINOLINE-BASED COMPOSITIONS FOR CANCER THERAPY | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2008-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146597-A1 | Therapeutic Tetrahydroisoquinoline-Based Compositions for Cancer Therapy | TP53, MCL1, HRAS | CYP3A4 4090/4885CYP2D6 4082/4885CYP2C19 4715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.